oral tirzepatide development status Safety and efficacy of as an add-on to single antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial Strive now has oral Tirzepatide

Pharmacokinetics The data for the PK of both drugs is widely available

The medical literature is not helping

Larger, longer trials are clearly needed to confirm these effects and to watch for late side effects

with a discount of up to 80%

Tanaka A, Ogawa M, Zhou Y, Namba K, Hendrickson RC, Miele MM, et al

While GLP-1s had mostly been prescribed for patients with type 2 diabetes as recently as two years ago (as of May 2024), the number of patients without a diabetes diagnosis using GLP-1s for weight loss has risen exponentially for example, they grew from 21K in 2019 to 174K in 2023, an increase of more than 700%